Globe Newswire

VANCOUVER, British Columbia, May 16, 2024 (GLOBE NEWSWIRE) -- EnWave Corporation (TSX-V:ENW | FSE:E4U) (“EnWave”, or the "Company") announced today it will report its financial results for the second quarter ended March 31, 2024 on Thursday, May 23, 2024 after market close. The financial statements and MD&A will be available on SEDAR+ at www.sedarplus.ca and on the Company’s website in the late evening Vancouver time.

The Company has scheduled a conference... (continue reading...)

Pan-RAS molecular glue ERAS-0015 and pan-KRAS inhibitor ERAS-4001 are potent, oral inhibitors with potential best-in-class profiles in RASm solid tumors

Pipeline prioritization and workforce restructuring sharpens focus on programs targeting the highest unmet needs and with highest probability of success

Priced concurrent $160 million equity offering

Erasca to host conference call and webcast Friday, May 17, 2024 at 8:30 am ET

SAN DIEGO, May 16, 2024 ... (continue reading...)

SAN DIEGO, May 16, 2024 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced the pricing of an underwritten offering of 86,486,486 shares of its common stock at a price of $1.85 per share. All of the shares to be sold in the offering are to be sold by Erasca. The gross proceeds to Erasca... (continue reading...)

NEW YORK, May 16, 2024 (GLOBE NEWSWIRE) --

WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Sonder Holdings Inc. (NASDAQ: SOND) between March 16, 2023 and March 15, 2024, both dates inclusive (the “Class Period”), of the important June 10, 2024 lead plaintiff deadline in the securities class action first filed by the Firm.

SO WHAT: If you purchased Sonder securities during the Class Period you may be entitled to... (continue reading...)

HONG KONG, SHANGHAI and FLORHAM PARK, N.J., May 17, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that topline and subgroup results from the ESLIM-01 Phase III study of sovleplenib, as well as new and updated data related to novel investigational hematological malignancy therapies HMPL-306, HMPL-760 and tazemetostat, will be presented at the upcoming European Hematology Association (“EHA”) Hybrid... (continue reading...)